DPM2 and breast cancer: Survival analysis using the KMplot breast cancer dataset showed that high transcriptional expression of DPM2 was significantly correlated with poor relapse-free survival (RFS) (Fig. 8d), and in basal-like breast cancer, in which drugs such as paclitaxel and docetaxel are widely recommended by guidelines, high DPM2 transcriptional expression was significantly negatively correlated with poor RFS in the tumors of patients (Fig. 8e).